Eli Lilly and Company reported third quarter results and ... In the following article, I will look at Eli Lilly once again and try to answer what perspective is correct. Should we actually be ...

Essence may receive compensation for some links to products and services on this website. Offers may be subject to change ...

Bad optics, that’s all I’ll say. For long-term success, Eli Lilly—or any company, for that matter—needs to perform in the short term while transforming for the long haul. That means ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. The reason for the disappointing sales, according to the ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other S&P 500 stocks. As per AXA Investment Managers, the US dominated financial markets this ...

Eli Lilly stock (NYSE: LLY) fell over 6% on Wednesday, October 30, after it posted downbeat results. The company reported revenue ... peers fare on metrics that matter. You will find other ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.

Shares of Eli Lilly and Co. slumped toward their biggest ... due to big misses in sales of anti-obesity drugs Mounjaro and Zepbound. The company said sales of Mounjaro and Zepbound were hurt ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. During an earnings call Wednesday, Eli Lilly instead blamed ...